Effects of prior or concurrent food restriction on amylin-induced changes in body weight and body composition in high-fat-fed female rats.
暂无分享,去创建一个
C. Anderson | J. Trevaskis | J. Roth | Holly Maier | T. Coffey | Heather Hughes | James L. Trevaskis
[1] L. Aronne,et al. Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity , 2008, Diabetes Care.
[2] P. Wielinga,et al. Modulation of the satiating effect of amylin by central ghrelin, leptin and insulin , 2007, Physiology & Behavior.
[3] J. Leahy,et al. Peroxisome Proliferator–Activated Receptor-γ Regulates Expression of PDX-1 and NKX6.1 in INS-1 Cells , 2007, Diabetes.
[4] R. Gill,et al. Induction of Indoleamine 2,3-Dioxygenase by Interferon-γ in Human Islets , 2007, Diabetes.
[5] C. Anderson,et al. Antiobesity effects of the beta-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression. , 2006, Endocrinology.
[6] E. Melanson,et al. Peripheral metabolic responses to prolonged weight reduction that promote rapid, efficient regain in obesity-prone rats. , 2006, American journal of physiology. Regulatory, integrative and comparative physiology.
[7] S. Heymsfield,et al. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. , 2005, The Journal of clinical investigation.
[8] R. Seeley,et al. The effect of the melanocortin agonist, MT-II, on the defended level of body adiposity. , 2005, Endocrinology.
[9] S. Doran,et al. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes , 2005, Diabetologia.
[10] O G Kolterman,et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long‐term glycaemic and weight control in Type 1 diabetes mellitus: a 1‐year, randomized controlled trial , 2004, Diabetic medicine : a journal of the British Diabetic Association.
[11] C. Weyer,et al. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. , 2004, Obesity research.
[12] C. Weyer,et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. , 2003, Diabetes care.
[13] E. Simon,et al. Salmon calcitonin – a potent inhibitor of food intake in states of impaired leptin signalling in laboratory rodents , 2002, The Journal of physiology.
[14] E. Scharrer,et al. The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema/nucleus of the solitary tract (AP/NTS) lesioned rats , 2001, International Journal of Obesity.
[15] B. Levin,et al. Sibutramine alters the central mechanisms regulating the defended body weight in diet-induced obese rats. , 2000, American journal of physiology. Regulatory, integrative and comparative physiology.
[16] S. Woods,et al. Amylin: a novel action in the brain to reduce body weight. , 2000, Endocrinology.
[17] S. Woods,et al. Amylin and insulin interact to reduce food intake in rats. , 2000, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[18] R. Considine,et al. Leptin and the regulation of body weight. , 1997, The international journal of biochemistry & cell biology.
[19] A. Young. Amylinʼs physiology and its role in diabetes , 1997 .
[20] N. Geary,et al. The increased satiating potency of CCK-8 by estradiol is not mediated by upregulation of NTS CCK receptors , 1996, Brain Research.
[21] E. Ravussin,et al. Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects , 1995, Nature Medicine.
[22] P. C. Butera,et al. Modulation of the satiety effect of cholecystokinin by estradiol , 1993, Physiology & Behavior.
[23] A. Young,et al. No measurable effect of amylin on lipolysis in either white or brown isolated adipocytes from rats , 1993 .
[24] Christine Jones,et al. Printed in Great Britain , 1970 .